Trial Profile
Phase I Study of the Non-receptor Kinase Inhibitor Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jun 2022
Price :
$35
*
At a glance
- Drugs Bosutinib (Primary) ; Pemetrexed (Primary)
- Indications Adenocarcinoma; Appendiceal cancer; Bladder cancer; Cervical cancer; Malignant thymoma; Malignant-mesothelioma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Solid tumours; Thymoma; Urethral cancer; Uterine cancer
- Focus Adverse reactions
- 10 Jun 2022 Status changed from recruiting to completed.
- 31 Jul 2021 Planned End Date changed from 1 Nov 2021 to 1 Dec 2022.
- 31 Jul 2021 Planned primary completion date changed from 1 Nov 2020 to 1 Dec 2022.